Teprotumumab
Teprotumumab
Teprotumumab (pronunciation: te-pro-tu-mu-mab) is a fully human monoclonal antibody that is used for the treatment of thyroid eye disease (TED). It is marketed under the brand name Tepezza by Horizon Therapeutics.
Etymology
The name Teprotumumab is derived from the International Nonproprietary Names (INN), where 'te' stands for therapeutic, 'pro' indicates the target (in this case, the insulin-like growth factor 1 receptor), 'tu' is the source (human), and 'mab' is indicative of its monoclonal antibody nature.
Mechanism of Action
Teprotumumab works by binding to the insulin-like growth factor 1 receptor (IGF-1R) on cells. This binding inhibits the activation of the receptor, which in turn reduces the symptoms of thyroid eye disease such as inflammation and tissue expansion.
Related Terms
See Also
External links
- Medical encyclopedia article on Teprotumumab
- Wikipedia's article - Teprotumumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski